You also shouldn't take Qsymia if you have glaucoma, hyperthyroidism, heart disease, or stroke
Graphical abstract Fig
This protocol was applied to exacerbate metabolic impairment in the models of PCOS, commonly seen in this syndrome, and as a means to define adverse conditions where to test the therapeutic potential of the selected multi-agonists
Available from: Brittany V B Johnson 1 , Mary Milstead 1 , Rachel Kreider 1 , Rachel Jones 1 Dietary supplement considerations during glucagon-like Peptide-1 receptor agonist treatment: A narrative review
Back Holst, JJ (1983) 'Gut glucagon, enteroglucagon, gut glucagon like immunoreactivity, Glicentin-current status'
This is an uncomfortable reality that most GLP-1 discussions avoid